Remarkable response to rituximab in a 72-year-old patient with refractory non-Hodgkin's lymphoma and marrow aplasia

Leuk Lymphoma. 2001 Jul;42(3):551-3. doi: 10.3109/10428190109064616.

Abstract

The chimeric human mouse antibody rituximab represents a substantial advance over the use of unmodified murine antibodies. Multicenter trials showed that rituximab induced remission in 48% of 166 relapsed lymphoma patients with minimal toxicity. Thus, the antibody might play a role in patients who cannot tolerate chemotherapy because of marrow aplasia. We observed a continuous complete remission induced by rituximab alone in a 72 year old patients with refractory and progressive high-grade non-Hodgkin's lymphoma (NHL) in the phase of chemotherapy induced marrow aplasia.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Blood Cell Count
  • Cyclophosphamide / administration & dosage
  • Humans
  • Lymph Nodes / pathology
  • Lymphoma, Non-Hodgkin / blood
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Lymphoma, Non-Hodgkin / pathology
  • Male
  • Pancytopenia / chemically induced*
  • Prednisone / administration & dosage
  • Red-Cell Aplasia, Pure / blood
  • Red-Cell Aplasia, Pure / chemically induced*
  • Rituximab
  • Treatment Outcome
  • Vidarabine / adverse effects*
  • Vidarabine / analogs & derivatives*
  • Vincristine / administration & dosage

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Rituximab
  • Vincristine
  • Cyclophosphamide
  • Vidarabine
  • fludarabine
  • Prednisone

Supplementary concepts

  • COP protocol 2